B-MS' ixabepilone NDA accepted by FDA

New Jersey, USA-based Bristol-Myers Squibb says that the Food and Drug Administration has accepted for review a New Drug Application for its developmental cancer therapeutic ixabepilone. Proposed indications for the agent include use as a monotherapy, or in combination with capecitabine, in the treatment of metastatic or locally-advanced breast cancer, after the failure of an anthracycline-based regimen, a taxane or capecitabine. The firm added that the FDA has earmarked the drug for priority review, and has set an action date of October this year.